Treatment of Metastatic Clear-Cell Renal Cell Carcinoma with IMDC Favourable Risk
Patients with metastatic clear-cell renal cell carcinoma classified as IMDC favourable risk represent a distinct clinical sub-population. Risk stratification at this level directly informs which evidence-based systemic regimens are appropriate.
Clinical Scenario
Metastatic clear-cell RCC with IMDC favourable risk classification. Accurate IMDC scoring is essential before regimen selection, as guideline-recommended options are specifically stratified by this risk category.
Treatment Approach (partial)
Several combination regimens are recommended for this population, encompassing immunotherapy-based and VEGF-targeted approaches. Subsequent therapy options and sequencing decisions depend on the first-line regimen used — the complete algorithm is in the full protocol.
References
- Offer pembrolizumab plus axitinib, lenvatinib plus pembrolizumab or nivolumab and cabozantinib or nivolumab plus ipilimumab or sunitinib or pazopanib for IMDC favourable risk disease.
- Offer carbozantinib or other VEGF-TKI as second-line therapy to patients' refractory to nivolumab plus ipilimumab or axitinib plus pembrolizumab or cabozantinib plus nivolumab or lenvatinib plus pembrolizumab.
- Offer nivolumab or cabozantinib for those patients who received first line VEGF targeted therapy alone.
View source ↗